Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study

BACKGROUND: Sunitinib is still one of the standard therapies in metastatic renal cell carcinoma (mRCC). Despite the benefit of sunitinib resistance will develop in the majority of patients. Most of them receive multiple sequential therapies during the course of disease. OBJECTIVES: To retrospectivel...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagyiványi, Krisztián, Budai, Barna, Gyergyay, Fruzsina, Küronya, Zsófia, Bíró, Krisztina, Géczi, Lajos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555772/
https://www.ncbi.nlm.nih.gov/pubmed/30915661
http://dx.doi.org/10.1007/s40261-019-00778-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555772/
https://www.ncbi.nlm.nih.gov/pubmed/30915661
http://dx.doi.org/10.1007/s40261-019-00778-5

Ejemplares similares